By contrast, it appeared that subjects with positive immunostaining for MMP-2, -8, -9, or -28 in the cancer cells or MMP-9 or ER-β in inflammatory cells would have a better prognosis than other patients (Table 3). This evidence concerns the gene ESR2 and cancer.